Analysis in the EMERGEncy Between TransVenous Cardiac PACIng Guided by Fluoroscopy Versus Echocardiogram (EMERG-TV-PAC)

October 23, 2018 updated by: University of Sao Paulo General Hospital

Prospective Analysis in the EMERGEncy Between TransVenous Cardiac PACIng Guided by Fluoroscopy Versus Echocardiogram

A lot of questions about use of temporary transvenous pacing still remain obscure and there is no effective comparison between use of fluoroscopy versus electrocardiogram/echocardiogram in patients with bradicardias. The aim of the study is to evaluate how long does it take to start the correct cardiac stimulation with transvenous pacing in patients with bradicardias comparing use of fluoroscopy versus electrocardiogram/echocardiogram and compare rates of complications between two methods.

Study Overview

Detailed Description

Approximately 150 subjects will be recruited over a planned recruitment period of 18 months. Patients will be submitted to ecchocardiogram using Philips Envisor, and electrocardiogram with Philips Healthcare PageWriter TC30.

Study Type

Interventional

Enrollment (Anticipated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • SP
      • São Paulo, SP, Brazil, 05.417-000
        • Recruiting
        • Instituto do Coração - HMFMUSP

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • adult males and females aged > 18 years
  • symptomatic bradicardia
  • informed consent signed.

Exclusion Criteria:

  • pregnancy
  • hemodynamic instability (pulmonary congestion / systolic arterial pressure lower than 90 mmHg)
  • body mass index greater than 40 kg/ m2
  • use of oral anticoagulation
  • acute coronary syndromes
  • left ventricle ejection fraction < 45%
  • presence of any kind of cardiac stimulation device

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: fluoroscopy
Transvenous cardiac estimulation
Other: ECG/ECHO
Transvenous cardiac estimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
all cause mortality
Time Frame: 1 week
1 week
infection
Time Frame: 1 week
Incidence of infection assessed by a clinical diagnosis
1 week
hematoma > 5 cm
Time Frame: 1 week
image
1 week
cardiac perforation
Time Frame: 1 week
Incidence of cardiac perforation assessed by a clinical diagnosis
1 week
pneumothorax
Time Frame: 1 week
Incidence of pneumothorax assessed by a clinical diagnosis
1 week
ventricular tachycardia
Time Frame: 1 week
Incidence of ventricular tachycardia assessed by an ECG test
1 week
loss of capture
Time Frame: 1 week
Incidence of loss of capture assessed by an ECG test
1 week
venous thrombosis
Time Frame: 1 week
Incidence of venous thrombosis assessed by an ultrasound
1 week
any complication the delays definitive pacemaker > 48 hours
Time Frame: 1 week
clinical diagnosis
1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to start the correct cardiac stimulation with transvenous pacing
Time Frame: 1 week
minutes scale
1 week
rates of success
Time Frame: 1 week
ECG test
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alexandre Soeiro, MD, Unidade Clínica de Emergência

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 16, 2017

Primary Completion (Anticipated)

December 1, 2018

Study Completion (Anticipated)

August 1, 2019

Study Registration Dates

First Submitted

January 18, 2017

First Submitted That Met QC Criteria

January 27, 2017

First Posted (Estimate)

January 31, 2017

Study Record Updates

Last Update Posted (Actual)

October 24, 2018

Last Update Submitted That Met QC Criteria

October 23, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bradycardia

Clinical Trials on Transvenous cardiac pacing guided by fluoroscopy

Subscribe